# Eastman Chemical Company (EMN) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/EMN/thesis · /stocks/EMN/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: EMN
step: "04"
title: Financial Snapshot — Three-Year P&L, Margins, and FCF
created: 2026-05-29
---

### Step 04 — Financial Snapshot

#### Three-Year Income Statement Summary

| Metric | FY2021 | FY2022 | FY2023 |
|--------|--------|--------|--------|
| Revenue ($B) | $10.48B | $10.59B | $9.21B |
| Gross Profit ($B) | ~$2.6B | ~$2.5B | ~$2.2B |
| Gross Margin % | ~24.8% | ~23.6% | ~23.9% |
| EBIT ($B) | ~$1.35B | ~$1.20B | ~$0.95B |
| EBIT Margin % | ~12.9% | ~11.3% | ~10.3% |
| EBITDA ($B) | ~$2.00B | ~$1.85B | ~$1.58B |
| EBITDA Margin % | ~19.1% | ~17.5% | ~17.2% |
| Adjusted EBITDA ($B) | ~$2.10B | ~$1.95B | ~$1.65B |
| Net Income (GAAP, $B) | ~$1.06B | ~$0.84B | ~$0.49B |
| Adjusted EPS | ~$9.20 | ~$8.65 | ~$7.43 |
| D&A ($B) | ~$0.65B | ~$0.65B | ~$0.63B |
| CapEx ($B) | ~$0.55B | ~$0.68B | ~$0.72B |
| Free Cash Flow ($B) | ~$1.10B | ~$0.85B | ~$0.87B |

**Note**: FY2022 revenue was the cycle peak — combination of volume recovery + raw material price pass-through inflation. FY2023 reflects volume headwinds from widespread destocking across chemical supply chains (customers drawing down inventories rather than placing new orders), most acute in Additives & Functional Products and Chemical Intermediates.

---

#### Revenue Bridge FY2022 → FY2023

| Driver | Impact |
|--------|--------|
| Volume/Mix (destocking) | -$800M to -$1.0B |
| Price normalization | -$400M to -$500M |
| Currency headwind (USD strength) | -$100M to -$150M |
| Fibers secular decline | -$50M to -$100M |
| Molecular recycling ramp (partial offset) | +$50-100M |
| **Net Change** | **~-$1.38B** |

---

#### Margin Analysis by Segment (FY2023)

| Segment | Revenue | EBITDA | EBITDA Margin |
|---------|---------|--------|---------------|
| Advanced Materials | ~$3.20B | ~$700-750M | ~22-24% |
| Additives & Functional Products | ~$2.30B | ~$430-500M | ~19-22% |
| Chemical Intermediates | ~$2.30B | ~$250-310M | ~11-14% |
| Fibers | ~$1.40B | ~$490-560M | ~35-40% |
| Corporate / Unallocated | — | ~$(150M) | — |
| **Consolidated** | **~$9.21B** | **~$1.65B** | **~17.9%** |

**Key observation**: The Fibers segment, despite being only ~15% of revenue, contributes approximately ~30% of consolidated EBITDA due to its exceptional margins. This makes Fibers' trajectory disproportionately important to consolidated EBITDA even as it declines in revenue terms.

---

#### Free Cash Flow Generation

| Metric | FY2021 | FY2022 | FY2023 |
|--------|--------|--------|--------|
| Operating Cash Flow ($B) | ~$1.65B | ~$1.53B | ~$1.59B |
| CapEx ($B) | ~$(0.55)B | ~$(0.68)B | ~$(0.72)B |
| Free Cash Flow ($B) | ~$1.10B | ~$0.85B | ~$0.87B |
| FCF Yield (vs. ~$8B mkt cap) | ~13.8% | ~10.6% | ~10.9% |
| FCF Conversion (% of EBITDA) | ~52% | ~46% | ~55% |

**FCF quality note**: Eastman's FCF has been consistently strong through cycles. The 2022-2023 dip reflects elevated CapEx for the molecular recycling facility (~$250M incremental spend). Working capital was a source of cash in 2023 (destocking = inventory drawdown). Maintenance CapEx ~$350-400M; growth CapEx (molecular recycling) ~$250-350M during investment phase.

---

#### Key Margin Dynamics

##### Gross Margin (23-25% range)
- Structurally limited by Chemical Intermediates and commodity components
- Advanced Materials gross margins ~40%+ vs. Chemical Intermediates ~15%
- Overall gross margin improving modestly as specialty mix increases

##### EBITDA Margin (17-20% target range)
- Management targets ~20%+ EBITDA margin on a normalized basis
- 2023 at ~17-18% reflects: (1) destocking volume deleverage, (2) molecular recycling startup costs, (3) high fixed cost base at Kingsport complex
- Recovery path: Volume normalization + molecular recycling revenue ramp = margin expansion toward 19-20% by FY2025-2026E

##### FCF Margin and Conversion
- FCF conversion of ~50-55% of EBITDA reflects: D&A of ~$630M; CapEx in elevated investment phase; working capital neutral to modest source
- Normalized FCF (post molecular recycling CapEx) ~$900M-$1.0B on ~$9.5B revenue = ~9.5-10.5% FCF margin

---

#### One-Time Items & Adjusted vs. GAAP

FY2023 GAAP net income of ~$490M included several significant non-cash charges:
- **Goodwill impairment**: ~$200M+ related to Additives segment (Taminco acquisition goodwill impaired on lower near-term earnings)
- **Asset impairments**: Fibers-related write-downs
- **Restructuring charges**: Plant rationalizations and headcount reduction

Adjusted EPS of ~$7.43 excludes these items. The gap between GAAP and adjusted earnings is persistent (~$1-2/share) — reflects Eastman's active portfolio management and the reality that some asset values (particularly in declining segments) require write-down over time.

---

#### Capital Structure Impact on Earnings

| Item | Impact |
|------|--------|
| Net Debt (~$4.5B at ~4.5% blended) | ~$200M annual interest expense |
| Interest Tax Shield (~25% rate) | ~$50M annual tax benefit |
| Share count (~130-135M diluted) | Lower share count vs. 5 years ago (buybacks) |
| Depreciation (~$630M) | Non-cash; adds back to EBITDA |

---

#### Forward-Looking Context

- **FY2024E**: Revenue ~$9.3-9.5B; Adjusted EPS ~$7.00-8.00; FCF ~$900M+
- **FY2025E**: Revenue ~$9.5-10.0B; Adjusted EPS ~$8.50-9.50; EBITDA margin ~18-19%
- Key upside: Molecular recycling ramp + volume recovery in Additives
- Key downside: Accelerated Fibers decline + European industrial recession

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/EMN/fundamental

## Navigation

- Overview: /stocks/EMN
- Financials (this page): /stocks/EMN/financials
- Thesis: /stocks/EMN/thesis
- Investment Memo: /stocks/EMN/memo
- Coverage universe: /stocks